A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Trial Profile

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Ixekizumab (Primary) ; Adalimumab
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-P1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Jun 2018 Results (n=417) published in the Rheumatology.
    • 20 Jun 2018 According to an Eli Lilly media release, Health Canada has approved Taltz (ixekizumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD). Taltz was granted a Notice of Compliance on March 29, 2018 based on results from this and SPIRIT-P2 clinical trials
    • 16 Jun 2018 Results (NCT01695239 and NCT02349295) presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top